Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Apr 20;4(4):CD012395.
doi: 10.1002/14651858.CD012395.pub2.

Pharmacological treatment for familial amyloid polyneuropathy

Francesca Magrinelli  1 , Gian Maria Fabrizi  1 , Lucio Santoro  2 , Fiore Manganelli  2 , Giampietro Zanette  3 , Tiziana Cavallaro  1 , Stefano Tamburin  1
Affiliations

Pharmacological treatment for familial amyloid polyneuropathy

Francesca Magrinelli et al. Cochrane Database Syst Rev. .

Abstract

Background: Disease-modifying pharmacological agents for transthyretin (TTR)-related familial amyloid polyneuropathy (FAP) have become available in the last decade, but evidence on their efficacy and safety is limited. This review focuses on disease-modifying pharmacological treatment for TTR-related and other FAPs, encompassing amyloid kinetic stabilisers, amyloid matrix solvents, and amyloid precursor inhibitors.

Objectives: To assess and compare the efficacy, acceptability, and tolerability of disease-modifying pharmacological agents for familial amyloid polyneuropathies (FAPs).

Search methods: On 18 November 2019, we searched the Cochrane Neuromuscular Specialised Register, the Cochrane Central Register of Controlled Trials, MEDLINE, and Embase. We reviewed reference lists of articles and textbooks on peripheral neuropathies. We also contacted experts in the field. We searched clinical trials registries and manufacturers' websites.

Selection criteria: We included randomised clinical trials (RCTs) or quasi-RCTs investigating any disease-modifying pharmacological agent in adults with FAPs. Disability due to FAP progression was the primary outcome. Secondary outcomes were severity of peripheral neuropathy, change in modified body mass index (mBMI), quality of life, severity of depression, mortality, and adverse events during the trial.

Data collection and analysis: We followed standard Cochrane methodology.

Main results: The review included four RCTs involving 655 people with TTR-FAP. The manufacturers of the drugs under investigation funded three of the studies. The trials investigated different drugs versus placebo and we did not conduct a meta-analysis. One RCT compared tafamidis with placebo in early-stage TTR-FAP (128 randomised participants). The trial did not explore our predetermined disability outcome measures. After 18 months, tafamidis might reduce progression of peripheral neuropathy slightly more than placebo (Neuropathy Impairment Score (NIS) in the lower limbs; mean difference (MD) -3.21 points, 95% confidential interval (CI) -5.63 to -0.79; P = 0.009; low-certainty evidence). However, tafamidis might lead to little or no difference in the change of quality of life between groups (Norfolk Quality of Life-Diabetic Neuropathy (Norfolk QOL-DN) total score; MD -4.50 points, 95% CI -11.27 to 2.27; P = 0.19; very low-certainty evidence). No clear between-group difference was found in the numbers of participants who died (risk ratio (RR) 0.65, 95% CI 0.11 to 3.74; P = 0.63; very low-certainty evidence), who dropped out due to adverse events (RR 1.29, 95% CI 0.30 to 5.54; P = 0.73; very low-certainty evidence), or who experienced at least one severe adverse event during the trial (RR 1.16, 95% CI 0.37 to 3.62; P = 0.79; very low-certainty evidence). One RCT compared diflunisal with placebo (130 randomised participants). At month 24, diflunisal might reduce progression of disability (Kumamoto Score; MD -4.90 points, 95% CI -7.89 to -1.91; P = 0.002; low-certainty evidence) and peripheral neuropathy (NIS plus 7 nerve tests; MD -18.10 points, 95% CI -26.03 to -10.17; P < 0.001; low-certainty evidence) more than placebo. After 24 months, changes from baseline in the quality of life measured by the 36-Item Short-Form Health Survey score showed no clear difference between groups for the physical component (MD 6.10 points, 95% CI 2.56 to 9.64; P = 0.001; very low-certainty evidence) and the mental component (MD 4.40 points, 95% CI -0.19 to 8.99; P = 0.063; very low-certainty evidence). There was no clear between-group difference in the number of people who died (RR 0.46, 95% CI 0.15 to 1.41; P = 0.17; very low-certainty evidence), in the number of dropouts due to adverse events (RR 2.06, 95% CI 0.39 to 10.87; P = 0.39; very low-certainty evidence), and in the number of people who experienced at least one severe adverse event (RR 0.77, 95% CI 0.18 to 3.32; P = 0.73; very low-certainty evidence) during the trial. One RCT compared patisiran with placebo (225 randomised participants). After 18 months, patisiran reduced both progression of disability (Rasch-built Overall Disability Scale; least-squares MD 8.90 points, 95% CI 7.00 to 10.80; P < 0.001; moderate-certainty evidence) and peripheral neuropathy (modified NIS plus 7 nerve tests - Alnylam version; least-squares MD -33.99 points, 95% CI -39.86 to -28.13; P < 0.001; moderate-certainty evidence) more than placebo. At month 18, the change in quality of life between groups favoured patisiran (Norfolk QOL-DN total score; least-squares MD -21.10 points, 95% CI -27.20 to -15.00; P < 0.001; low-certainty evidence). There was little or no between-group difference in the number of participants who died (RR 0.61, 95% CI 0.21 to 1.74; P = 0.35; low-certainty evidence), dropped out due to adverse events (RR 0.33, 95% CI 0.13 to 0.82; P = 0.017; low-certainty evidence), or experienced at least one severe adverse event (RR 0.91, 95% CI 0.64 to 1.28; P = 0.58; low-certainty evidence) during the trial. One RCT compared inotersen with placebo (172 randomised participants). The trial did not explore our predetermined disability outcome measures. From baseline to week 66, inotersen reduced progression of peripheral neuropathy more than placebo (modified NIS plus 7 nerve tests - Ionis version; MD -19.73 points, 95% CI -26.50 to -12.96; P < 0.001; moderate-certainty evidence). At week 65, the change in quality of life between groups favoured inotersen (Norfolk QOL-DN total score; MD -10.85 points, 95% CI -17.25 to -4.45; P < 0.001; low-certainty evidence). Inotersen may slightly increase mortality (RR 5.94, 95% CI 0.33 to 105.60; P = 0.22; low-certainty evidence) and occurrence of severe adverse events (RR 1.48, 95% CI 0.85 to 2.57; P = 0.16; low-certainty evidence) compared to placebo. More dropouts due to adverse events were observed in the inotersen than in the placebo group (RR 8.57, 95% CI 1.16 to 63.07; P = 0.035; low-certainty evidence). There were no studies addressing apolipoprotein AI-FAP, gelsolin-FAP, and beta-2-microglobulin-FAP.

Authors' conclusions: Evidence on the pharmacological treatment of FAPs from RCTs is limited to TTR-FAP. No studies directly compare disease-modifying pharmacological treatments for TTR-FAP. Results from placebo-controlled trials indicate that tafamidis, diflunisal, patisiran, and inotersen may be beneficial in TTR-FAP, but further investigations are needed. Since direct comparative studies for TTR-FAP will be hampered by sample size and costs required to demonstrate superiority of one drug over another, long-term non-randomised open-label studies monitoring their efficacy and safety are needed.

PubMed Disclaimer

Conflict of interest statement

FM: was sponsored by Pfizer Inc. to attend the ARiA (Advances and Research in TTR Amyloidosis) VI Symposium in Wien in 2017.

GMF: Gian Maria Fabrizi was sponsored by: Akcea Therapeutics to attend the 2019 American Academy of Neurology Conference in Philadelphia and by Pfizer Inc. to attend the 2018 ARia (Advances and Research in TTR Amyloidosis) VII symposium, in Frankfurt. GMF received fees for Board membership from Akcea Therapeutics (Akcea Scientific Advisory Board, Milan January 29 2019) and Alnylam Pharmaceuticals (Alnylam Scientific Advisory Board, Milan December 11 2019).

LS: none known.

FioM: none known.

GZ: none known.

TC: received fees from Pfizer Inc. for her participation as member of the Advisory Board "Amiloidosi ereditaria TTR correlata" (Milan, 2016).

ST: none known; ST is a specialist in neurology and manages people with peripheral neuropathies, including familial amyloid polyneuropathy.

The review is not compliant with Cochrane Commercial Sponsorship policy; the update will have a majority of authors and lead author free of conflicts.

Figures

1
1
PRISMA chart for searched to included studies for FAPs
2
2
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
See this image and copyright information in PMC

Update of

  • doi: 10.1002/14651858.CD012395

References

References to studies included in this review

Adams 2018 {published data only (unpublished sought but not used)}
    1. Adams D, Gonzalez‐Duarte A, O'Riordan W, Yang CC, Yamashita T, Kristen A, et al. Evaluation of quality of life and disability in patients with hereditary transthyretin‐mediated (HATTR) amyloidosis with polyneuropathy following treatment with patisiran, an investigational RNAI therapeutic:results from the phase 3 APOLLO study. Neurology 2018;90(15 Suppl 1):S31.003. [EMBASE: 622309208]
    1. Adams D, Gonzalez‐Duarte A, O'Riordan W, Yang CC, Yamashita T, Kristen A, et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Neurology 2018;90(15 Suppl 1):CT.001. [EMBASE: 622307825]
    1. Adams D, Gonzalez‐Duarte A, O'Riordan W, Yang CC, Yamashita T, Kristen A, et al. Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin‐mediated (hATTR) amyloidosis with polyneuropathy: results from the phase 3 APOLLO study. Orphanet Journal of Rare Diseases 2017;12(Suppl 1):165. [EMBASE: 619389882]
    1. Adams D, Gonzalez‐Duarte A, O'Riordan WD, Yang CC, Ueda M, Kristen AV, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. New England Journal of Medicine 2018;379(1):11‐21. [PUBMED: 29972753 ] - PubMed
    1. Adams D, Pritesh JG. Outcomes of patients with hereditary transthyretin‐mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a phase 3 study of patisiran. Revue Neurologique 2019;175(Suppl 1):S129.
Benson 2018 {published data only}
    1. Anonymous. Improvement in quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy treated with inotersen in the phase 3 study NEURO‐TTR. Heart & Lung 2019;48(5):469‐71.
    1. Benson M, Kincaid J, Ackermann E, Monia B. A phase 3 study to evaluate ISIS‐TTRRX in patients with transthyretin familial amyloid polyneuropathy (TTRFAP): study design and baseline demographics. Neurology 2015;84(14 Suppl):S50.006. [EMBASE: 71922192 ]
    1. Benson M, Waddington‐Cruz M, Wang A, Polydefkis M, Plante‐Bordeneuve V, Berk J, et al. Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis with polyneuropathy (hATTR‐PN). Orphanet Journal of Rare Diseases 2017;12(Suppl 1):165‐6. [EMBASE: 619389834]
    1. Benson MD, Waddington‐Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. New England Journal of Medicine 2018;379(1):22‐31. [PUBMED: 29972757] - PubMed
    1. Coelho T, Wang A, Waddington‐Cruz M, Polydefkis M, Dyck P, Scheinberg M, et al. Inotersen improves quality of life and neuropathy in patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy: results of the phase 3 study NEURO‐TTR. European Journal of Neurology 2018;25(Suppl 2):376. [EMBASE: 623298254]
Berk 2013 {published data only}
    1. Berk JL, Dyck PJ, Obici L, Zeldenrust SR, Sekijima Y, Yamashita T, et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid 2010;17(Suppl 1):78. [EMBASE: 70725032] - PubMed
    1. Berk JL, Dyck PJ, Obici L, Zeldenrust SR, Sekijima Y, Yamashita T, et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid 2011;18(Suppl 1):196‐7. [PUBMED: 21838485] - PubMed
    1. Berk JL, Suhr OB, Obici L, Sekijima Y, Zeldenrust SR, Yamashita T, et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA 2013;310(24):2658–67. [PUBMED: 24368466] - PMC - PubMed
    1. Berk JL, Suhr OB, Sekijima Y, Yamashita T, Heneghan M, Zeldenrust SR, et al. The Diflunisal Trial: study accrual and drug tolerance. Amyloid 2012;19(Suppl 1):37‐8. [PUBMED: 22551208] - PubMed
Coelho 2012 {published data only (unpublished sought but not used)}
    1. Coelho T. Tafamidis: a novel and effective oral treatment for familial amyloid neuropathies. European Journal of Neurology 2012;19(Suppl 1):8. [EMBASE: 70938581]
    1. Coelho T, Maia L, Martins Da Silva A, Waddingtion‐Cruz M, Plante‐Bordeneuve V, Lozeron P, et al. Tafamidis (Fx‐1006A): A first‐in‐class disease‐modifying therapy for transthyretin familial amyloid. Amyloid 2010;17(Suppl 1):75‐6. [EMBASE: 70725028]
    1. Coelho T, Maia L, Martins Da Silva A, Waddingtion‐Cruz M, Plante‐Bordeneuve V, Lozeron P, et al. Tafamidis and nerve fiber function in transthyretin‐type familial amyloid polyneuropathy. Clinical Neurophysiology 2012;123(6):e56. [EMBASE: 70824746]
    1. Coelho T, Maia L, Martins Da Silva A, Waddingtion‐Cruz M, Plante‐Bordeneuve V, Suhr OB, et al. A landmark clinical trial of a novel small molecule transthyretin stabilizer, Fx‐1006A, in patients with TTR amyloid polyneuropathy: a phase II/III randomized, double‐blind, placebo‐controlled study. Journal of the Peripheral Nervous System 2009;14(Suppl 2):35‐6. [EMBASE: 70008473]
    1. Coelho T, Maia LF, Martins da Silva A, Waddington‐Cruz M, Planté‐Bordeneuve V, Lozeron P, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology 2012;79(8):785‐92. [PUBMED: 22843282] - PMC - PubMed

References to studies excluded from this review

Adams 2015 {published data only}
    1. Adams D, Coelho T, Conceicao I, Waddington Cruz M, Schmidt H, Buades J, et al. Phase 2 open‐label extension (OLE) study of patisiran for the treatment of hereditary ATTR (hATTR) amyloidosis: 24‐month safety and efficacy in subgroup of patients with cardiac involvement. European Journal of Heart Failure 2017;19(Suppl S1):19.
    1. Adams D, Coelho T, Conceicao I, Waddington‐Cruz M, Schmidt H, Buades J, et al. Phase 2 open‐label extension (OLE) study of patisiran with or without a TTR stabilizer for the treatment of hereditary ATTR (hATTR) amyloidosis with polyneuropathy. European Journal of Neurology 2017;24(Suppl 1):31‐2.
    1. Adams D, Coelho T, Conceicao I, Waddington‐Cruz M, Schmidt H, Buades J, et al. Phase 2 open‐label extension (OLE) study of patisiran, an investigational RNA interference (RNAi) therapeutic for the treatment of hereditary attr amyloidosis with polyneuropathy. Value in Health 2017;20(5):A211‐2.
    1. Adams D, Suhr O, Conceicao I, Waddington‐Cruz M, Schmidt H, Buades J, et al. Phase 2 open‐label extension (OLE) study of patisiran, an investigational siRNA agent for familial amyloidotic polyneuropathy (FAP). Orphanet Journal of Rare Diseases 2015;10:1‐2.
Barroso 2017 {published data only}
    1. Barroso FA, Judge DP, Ebede B, Li H, Stewart M, Amass L, et al. Long‐term safety and efficacy of tafamidis for the treatment of hereditary transthyretin amyloid polyneuropathy: results up to 6 years. Amyloid 2017;24(3):194‐204. - PubMed
Coelho 2013 {published data only}
    1. Coelho T, Maia LF, Silva AM, Waddington‐Cruz M, Planté‐Bordeneuve V, Suhr OB, et al. Long‐term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. Journal of Neurology 2013;260(11):2802‐14. - PMC - PubMed
Gillmore 2015 {published data only}
    1. Gillmore JD, Falk RH, Maurer MS, Hanna M, Karsten V, Vest J, et al. Phase 2, open‐label extension (OLE) study of revusiran, an investigational RNAi therapeutic for the treatment of patients with transthyretin cardiac amyloidosis. Orphanet Journal of Rare Diseases 2015;10:1‐2.
Gundapaneni 2018 {published data only}
    1. Gundapaneni B, Sultan MB, Keohane DJ, Schwartz J. Tafamidis delays disease progression comparably across Val30Met and non‐Val30Met genotypes in transthyretin familial amyloid polyneuropathy. Journal of the Peripheral Nervous System 2017;22(3):294. - PMC - PubMed
    1. Gundapaneni BK, Sultan MB, Keohane DJ, Schwartz JH. Tafamidis delays disease progression comparably across Val30Met and non‐Val30Met genotypes in transthyretin familial amyloid polyneuropathy. Orphanet Journal of Rare Diseases 2017;12(Suppl 1):165.
    1. Gundapaneni BK, Sultan MB, Keohane DJ, Schwartz JH. Tafamidis delays neurological progression comparably across Val30Met and non‐Val30Met genotypes in transthyretin familial amyloid polyneuropathy. European Journal of Neurology 2018;25(3):464‐8. - PMC - PubMed
Maurer 2018 {published data only}
    1. Maurer MS, Elliott P, Merlini G, Shah SJ, Waddington‐Cruz M, Flynn A, et al. Design and rationale of the phase 3 ATTR‐ACT clinical trial (Tafamidis in Transthyretin Cardiomyopathy Clinical Trial). Circulation: Heart Failure 2017;10(6):e003815. - PubMed
    1. Maurer MS, Schwartz JH, Gundapaneni B, Perry M, Merlini G, Waddington‐Cruz M, et al. Treatment for patients with transthyretin amyloid cardiomyopathy. New England Journal of Medicine 2018;379(11):1007‐16. - PubMed
Plante‐Bordeneuve 2018 {published data only}
    1. Dasgupta NR, Falk RH, Drachman BM, Maurer MS, Whelan CJ, Brannagan T, et al. Safety of inotersen treatment in patients with transthyretin amyloid cardiomyopathy. Journal of the American College of Cardiology 2019;73(9 Suppl 1):909.
    1. Plante‐Bordeneuve V, Brannagan T, Wang A, Coelho T, Waddington‐Cruz M, Polydefkis M, et al. Long‐term efficacy and safety of Inotersen in patients with hereditary transthyretin (hATTR) amyloidosis treated in the open‐label extension of the phase‐3 study NEURO‐TTR. European Journal of Neurology 2018;25(Suppl 2):30.
Russo 2013 {published data only}
    1. Russo M, Obici L, Calabrese D, Piscosquito G, Luigetti M, Manganelli F, et al. Neurological data collection protocol on tafamidis meglumine treatment for familial amyloid polyneuropathy: Preliminary data on patients enrolled by the Italian network. Journal of the Peripheral Nervous System 2013;18:S99.
    1. Russo M, Stancanelli C, Gentile L, Toscano A, Vita G, Mazzeo A. Safety and tolerability of orally administered tafamidis meglumine in TTR FAP: Preliminary data at 3‐month follow‐up. Journal of the Peripheral Nervous System 2012;17:S48‐9.
Sah 2011 {published data only}
    1. Sah DWY, Chen Q, Costelha S, Butler J, Fishman S, Rossomando A, et al. ALN‐TTR, an RNAI therapeutic for the treatment of transthyretin amyloidosis. Nucleic Acid Therapeutics 2011;21(5):A55‐6.
Suhr 2015 {published data only}
    1. Suhr OB, Coelho T, Buades J, Pouget J, Conceicao I, Berk J, et al. Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi‐dose study. Orphanet Journal of Rare Diseases 2015;10:109. - PMC - PubMed
Waddington‐Cruz 2016 {published data only}
    1. Waddington‐Cruz M, Amass L, Keohane D, Schwartz J, Gundapaneni B, Li H. Early intervention with tafamidis provides long‐term benefit in delaying neurological progression in patients with transthyretin familial amyloid polyneuropathy. Orphanet Journal of Rare Diseases 2015;10(Suppl 1):P6.
    1. Waddington‐Cruz M, Amass L, Keohane D, Schwartz J, Li H, Gundapaneni B. Early intervention with tafamidis provides long‐term (5.5‐year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathy. Amyloid 2016;23(3):178‐83. - PMC - PubMed
    1. Waddington‐Cruz M, Amass L, Keohane DJ, Schwartz J, Li H, Gundapaneni B. Early intervention with tafamidis provides long‐term benefit in delaying neurological progression in patients with transthyretin familial amyloid polyneuropathy. Journal of the Peripheral Nervous System 2015;20(2):244.

Additional references

Abbott 2002
    1. Abbott CA, Carrington AL, Ashe H, Bath S, Every LC, Griffiths J, et al. The North‐West Diabetes Foot Care Study: incidence of, and risk factors for, new diabetic foot ulceration in a community‐based patient cohort. Diabetic Medicine 2002;19(5):377‐84. - PubMed
Adams 2013
    1. Adams D. Recent advances in the treatment of familial amyloid polyneuropathy. Therapeutic Advances in Neurological Disorders 2013;6(2):129‐39. - PMC - PubMed
Adams 2014
    1. Adams A, Théaudin M, Cauquil C, Algalarrondo V, Slama M. FAP neuropathy and emerging treatments. Current Neurology and Neuroscience Reports 2014;14(3):435‐46. - PubMed
Andrade 1952
    1. Andrade C. A peculiar form of peripheral neuropathy; familiar atypical generalized amyloidosis with special involvement of the peripheral nerves. Brain 1952;75(3):408–27. - PubMed
Beck 1988
    1. Beck AT, Steer RA, Garbin MG. Psychometric properties of the Beck Depression Inventory: twenty‐five years of evaluation. Clinical Psychology Review 1988;8(1):77‐100.
Bril 1999
    1. Bril V. NIS‐LL: the primary measurement scale for clinical trial endpoints in diabetic peripheral neuropathy. European Neurology 1999;41(Suppl 1):8‐13. - PubMed
Cardoso 2006
    1. Cardoso I, Saraiva MJ. Doxycycline disrupts transthyretin amyloid: evidence from studies in a FAP transgenic mice model. FASEB Journal 2006;20(2):234‐9. - PubMed
Cardoso 2010
    1. Cardoso I, Martins D, Ribeiro T, Merlini G, Saraiva MJ. Synergy of combined Doxycycline/TUDCA treatment in lowering Transthyretin deposition and associated biomarkers: studies in FAP mouse models. Journal of Translational Medicine 2010;8:74. - PMC - PubMed
Castro 2016
    1. Castro J, Miranda B, Castro I, Carvalho M, Conceição I. The diagnostic accuracy of Sudoscan in transthyretin familial amyloid polyneuropathy. Clinical Neurophysiology 2016;127(5):2222‐7. - PubMed
Chiang 2015
    1. Chiang MC, Tseng MT, Pan CL, Chao CC, Hsieh ST. Progress in the treatment of small fiber peripheral neuropathy. Expert Review of Neurotherapeutics 2015;15(3):305‐13. - PubMed
Coelho 2017
    1. Coelho T, Vinik A, Vinik EJ, Tripp T, Packman J, Grogan DR. Clinical measures in transthyretin familial amyloid polyneuropathy. Muscle & Nerve 2017;55(3):323‐32. - PubMed
Coutinho 1980
    1. Coutinho P, Martins da Silva A, Lopes Lima J, Resende Barbosa A. Forty years of experience with type I amyloid neuropathy. Review of 483 cases. In: Glenner G, Costa P, Freitas A editor(s). Amyloid and Amyloidosis. Amsterdam: Execerpta Medica, 1980:88‐98.
Covidence [Computer program]
    1. Veritas Health Innovation. Covidence. Melbourne, Australia: Veritas Health Innovation, Version accessed 10 January 2017.
Denier 2007
    1. Denier C, Ducot B, Husson H, Lozeron P, Adams D, Meyer L, et al. A brief compound test for assessment of autonomic and sensory‐motor dysfunction in familial amyloid polyneuropathy. Journal of Neurology 2007;254(12):1684–8. - PubMed
Dubrey 2015
    1. Dubrey S, Ackermann E, Gillmore J. The transthyretin amyloidoses: advances in therapy. Postgraduate Medical Journal 2015;91(1078):439‐48. - PubMed
Dyck 1995
    1. Dyck PJ, Litchy WJ, Lehman KA, Hokanson JL, Low PA, O'Brien PC. Variables influencing neuropathic endpoints: the Rochester Diabetic Neuropathy Study of Healthy Subjects. Neurology 1995;45(6):1115‐21. - PubMed
Dyck 1997
    1. Dyck PJ, Davies JL, Litchy WJ, O’Brien PC. Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort. Neurology 1997;49(1):229‐39. - PubMed
Dyck 2017
    1. Dyck PJ, Kincaid JC, Dyck PJ, Chaudhry V, Goyal NA, Alves C, et al. Assessing mNIS+7Ionis and international neurologists' proficiency in a familial amyloidotic polyneuropathy trial. Muscle & Nerve 2017;56(5):901‐11. - PMC - PubMed
Ferreira 2012
    1. Ferreira N, Saraiva MJ, Almeida MR. Epigallocatechin‐3‐gallate as a potential therapeutic drug for TTR‐related amyloidosis: "in vivo" evidence from FAP mice models. PLoS One 2012;7(1):e29933. - PMC - PubMed
Hamilton 1960
    1. Hamilton M. A rating scale for depression. Journal of Neurology, Neurosurgery & Psychiatry 1960;23:56‐62. - PMC - PubMed
Higgins 2011
    1. Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Hund 2012
    1. Hund E. Familial amyloidotic polyneuropathy: current and emerging treatment options for transthyretin‐mediated amyloidosis. The Application of Clinical Genetics 2012;5:37‐41. - PMC - PubMed
Kempler 2011
    1. Kempler P, Amarenco G, Freeman R, Frontoni S, Horowitz M, Stevens M, et al. Management strategies for gastrointestinal, erectile, bladder, and sudomotor dysfunction in patients with diabetes. Diabetes/Metabolism Research and Reviews 2011;27(7):665‐77. - PubMed
Kollmer 2015
    1. Kollmer J, Hund E, Hornung B, Hegenbart U, Schönland SO, Kimmich C, et al. In vivo detection of nerve injury in familial amyloid polyneuropathy by magnetic resonance neurography. Brain 2015;138(Pt 3):549‐62. - PMC - PubMed
Kollmer 2017
    1. Kollmer J, Sahm F, Hegenbart U, Purrucker JC, Kimmich C, Schönland SO, et al. Sural nerve injury in familial amyloid polyneuropathy: MR neurography vs clinicopathologic tools. Neurology 2017;89(5):475‐84. - PubMed
Kristen 2012
    1. Kristen AV, Lehrke S, Buss S, Mereles D, Steen H, Ehlermann P, et al. Green tea halts progression of cardiac transthyretin amyloidosis: an observational report. Clinical Research in Cardiology 2012;101(10):805‐13. - PMC - PubMed
Lacomblez 1989
    1. Lacomblez L, Bouche P, Bensimon G, Meininger V. A double‐blind, placebo‐controlled trial of high doses of gangliosides in amyotrophic lateral sclerosis. Neurology 1989;39(12):1635–7. - PubMed
Lozeron 2013
    1. Lozeron P, Théaudin M, Mincheva Z, Ducot B, Lacroix C, Adams D, French Network for FAP (CORNAMYL). Effect on disability and safety of Tafamidis in late onset of Met30 transthyretin familial amyloid polyneuropathy. European Journal of Neurology 2013;20(12):1539‐45. - PubMed
Lunn 2016
    1. Lunn M, Hanna M, Howard R, Parton M, Rahman S, Reilly M, et al. Nerve and muscle disease. In: Clarke C, Howard R, Rossor M, Shorvon S editor(s). Neurology: a Queen Square Textbook. 2nd Edition. Oxford, UK: Wiley Blackwell, 2016:391‐473.
Mariani 2015
    1. Mariani LL, Lozeron P, Théaudin M, Mincheva Z, Signate A, Ducot B, et al. Genotype‐phenotype correlation and course of transthyretin familial amyloid polyneuropathies in France. Annals of Neurology 2015;78(6):901‐16. - PMC - PubMed
Masuda 2017
    1. Masuda T, Ueda M, Suenaga G, Misumi Y, Tasaki M, Izaki A, et al. Early skin denervation in hereditary and iatrogenic transthyretin amyloid neuropathy. Neurology 2017;88(23):2192‐7. - PubMed
Maule 2007
    1. Maule S, Papotti G, Naso D, Magnino C, Testa E, Veglio F. Orthostatic hypotension: evaluation and treatment. Cardiovascular & Hematological Disorders Drug Targets 2007;7(1):63‐70. - PubMed
Merlini 2013
    1. Merlini G, Planté‐Bordeneuve V, Judge DP, Schmidt H, Obici L, Perlini S, et al. Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non‐Val30Met transthyretin amyloidosis. Journal of Cardiovascular Translational Research 2013;6(6):1011‐20. - PMC - PubMed
Moher 2009
    1. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta‐Analyses: The PRISMA Statement. PLoS Medicine 2009;6(7):e1000097. [DOI: 10.1371/journal.pmed1000097] - DOI - PMC - PubMed
Murphy 2011
    1. Murphy SM, Herrmann DN, McDermott MP, Scherer SS, Shy ME, Reilly MM, et al. Reliability of the CMT neuropathy score (second version) in Charcot‐Marie‐Tooth disease. Journal of the Peripheral Nervous System 2011;16(3):191‐8. - PMC - PubMed
Nasr 2017
    1. Nasr SH, Dasari S, Mills JR, Theis JD, Zimmermann MT, Fonseca R, et al. Hereditary lysozyme amyloidosis variant p.Leu102Ser associates with unique phenotype. Journal of the American Society of Nephrology 2017;28(2):431‐8. - PMC - PubMed
Obici 2012
    1. Obici L, Cortese A, Lozza A, Lucchetti J, Gobbi M, Palladini G, et al. Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study. Amyloid 2012;19(Suppl 1):34‐6. - PubMed
Planté‐Bordeneuve 2011
    1. Planté‐Bordeneuve V, Said G. Familial amyloid polyneuropathy. Lancet Neurology 2011;10(12):1086‐97. - PubMed
Planté‐Bordeneuve 2018
    1. Planté‐Bordeneuve V. Transthyretin familial amyloid polyneuropathy: an update. Journal of Neurology 2018;265(4):976‐83. - PubMed
PNS 1995
    1. Peripheral Nerve Society. Diabetic polyneuropathy in controlled clinical trials: consensus report of the Peripheral Nerve Society. Annals of Neurology 1995;38(3):478–82. [DOI: 10.1002/ana.410380323; PUBMED: 7668839] - DOI - PubMed
Rabin 2001
    1. Rabin R, Charro F. EQ‐5D: a measure of health status from the EuroQolGroup. Annals of Medicine 2001;33(5):337‐43. - PubMed
Rapezzi 2010
    1. Rapezzi C, Quarta CC, Riva L, Longhi S, Gallelli I, Lorenzini M, et al. Transthyretin‐related amyloidoses and the heart: a clinical overview. Nature Reviews. Cardiology 2010;7(7):398‐408. - PubMed
Rapezzi 2013
    1. Rapezzi C, Quarta CC, Obici L, Perfetto F, Longhi S, Salvi F, et al. Disease profile and differential diagnosis of hereditary transthyretin‐related amyloidosis with exclusively cardiac phenotype: an Italian perspective. European Heart Journal 2013;34(7):520‐8. - PubMed
Reig 2015
    1. Reig N, Ventura S, Salvadó M, Gámez J, Insa R. SOM0226, a repositioned compound for the treatment of TTR amyloidosis. Orphanet Journal of Rare Disease 2015;10(Suppl 1):P9.
Review Manager 2014 [Computer program]
    1. Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Rowczenio 2014
    1. Rowczenio DM, Noor I, Gillmore JD, Lachmann HJ, Whelan C, Hawkins PN, et al. Online registry for mutations in hereditary amyloidosis including nomenclature recommendations. Human Mutation 2014;35(9):E2403‐12. [10.1002/humu.22619] - PubMed
Rowczenio 2015
    1. Rowczenio D, Wechalekar A. Mutations in transthyretin gene. amyloidosismutations.com/mut‐attr.php 2015.
Sales‐Luís 1990
    1. Sales‐Luís ML, Galvão M, Sousa G, Alves MM, Serrão R. Plasma exchanges on: the treatment of familial amyloidotic polyneuropathy, Portuguese type. Familial amyloidotic polyneuropathy and other transthyretin related disorders. Arquivos de Medicina 1990;3:361‐9.
Sant'Anna 2016
    1. Sant'Anna R, Gallego P, Robinson LZ, Pereira‐Henriques A, Ferreira N, Pinheiro F, et al. Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity. Nature Communications 2016;7:10787. - PMC - PubMed
SF‐36v2 2011
    1. User's manual for the SF‐36v2 survey. 3rd ed. Lincoln (RD), Quality Metric Incorporated 2011.
Shy 2005
    1. Shy ME, Blake J, Krajewski K, Fuerst DR, Laura M, Hahn AF, et al. Reliability and validity of the CMT neuropathy score as a measure of disability. Neurology 2005;64(7):1209‐14. - PubMed
Sipe 2014
    1. Sipe JD, Benson MD, Buxbaum JN, Ikeda S, Merlini G, Saraiva MJ, et al. Nomenclature 2014: amyloid fibril proteins and clinical classification of the amyloidosis. Amyloid 2014;21(4):221‐4. - PubMed
Steen 1983
    1. Steen L, Ek B. Familial amyloidosis with polyneuropathy. A long‐term follow‐up of 21 patients with special reference to gastrointestinal symptoms. Acta Medica Scandinavica 1983;214:387–97. - PubMed
Suanprasert 2014
    1. Suanprasert N, Berk JL, Benson MD, Dyck PJ, Klein CJ, Gollob JA, et al. Retrospective study of a TTR FAP cohort to modify NIS+7 for therapeutic trials. Journal of the Neurological Sciences 2014;344(1‐2):121‐8. - PubMed
Suhr 1984
    1. Suhr O, Danielsson A, Holmgren G, Steen L. Malnutrition and gastrointestinal dysfunction as prognostic factors for survival in familial amyloidotic polyneuropathy. Journal of Internal Medicine 1994;235(5):479‐85. - PubMed
Tashima 1999
    1. Tashima K, Ando Y, Terazaki H, Yoshimatsu S, Suhr OB, Obayashi K, et al. Outcome of liver transplantation for transthyretin amyloidosis: follow‐up of Japanese familial amyloidotic polyneuropathy patients. Journal of the Neurological Sciences 1999;171(1):19‐23. - PubMed
Valleix 2012
    1. Valleix S, Gillmore JD, Bridoux F, Mangione PP, Dogan A, Nedelec B, et al. Hereditary Systemic Amyloidosis Due to Asp76Asn Variant β2‐Microglobulin. New England Journal of Medicine 2012;366(24):2276‐83. - PubMed
van Nes 2011
    1. Nes SI, Vanhoutte EK, Doorn PA, Hermans M, Bakkers M, Kuitwaard K, et al. Rasch‐built Overall Disability Scale (R‐ODS) for immune‐mediated peripheral neuropathies. Neurology 2011;76(4):337‐45. - PubMed
Vinik 2005
    1. Vinik EJ, Hayes RP, Oglesby A, Bastyr E, Barlow P, Ford‐Molvik SL, et al. The development and validation of the Norfolk QOL‐DN, a new measure of patients’ perception of the effects of diabetes and diabetic neuropathy. Diabetes Technology & Therapeutics 2005;7(3):497‐508. - PubMed
Ware 1992
    1. Ware JE Jr, Sherbourne CD. The MOS 36‐item short‐form health survey (SF‐36). I. Conceptual framework and item selection. Medical Care 1992;30(6):473–83. - PubMed
Yamamoto 2007
    1. Yamamoto S, Wilczek H, Nowak G, Larsson M, Oksanen A, Iwata T, et al. Liver transplantation for familial amyloidotic polyneuropathy (FAP): a single‐center experience over 16 years. American Journal of Transplantation 2007;7(11):2597–604. - PubMed
Yates 1980
    1. Yates JW, Chalmer B, McKegney FP. Evaluation of patients with advanced cancer using the Karnofsky performance status. Cancer 1980;45:2220–4. - PubMed

References to other published versions of this review

Magrinelli 2016
    1. Magrinelli F, Fabrizi GM, Santoro L, Manganelli F, Cavallaro T, Zanette G, et al. Pharmacological treatment for familial amyloid neuropathy. Cochrane Database of Systematic Reviews 2016, Issue 10. [DOI: 10.1002/14651858.CD012395] - DOI - PMC - PubMed

Publication types

MeSH terms

Supplementary concepts